ECSP088082A - Derivados de piridazina - Google Patents

Derivados de piridazina

Info

Publication number
ECSP088082A
ECSP088082A EC2008008082A ECSP088082A ECSP088082A EC SP088082 A ECSP088082 A EC SP088082A EC 2008008082 A EC2008008082 A EC 2008008082A EC SP088082 A ECSP088082 A EC SP088082A EC SP088082 A ECSP088082 A EC SP088082A
Authority
EC
Ecuador
Prior art keywords
piridazine
derivatives
esters
compounds
formula
Prior art date
Application number
EC2008008082A
Other languages
English (en)
Inventor
Bernd Kuhn
Kurt Amrein
Alexander V Mayweg
Werner Neidhart
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36781523&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP088082(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of ECSP088082A publication Critical patent/ECSP088082A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/08—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/28—Cinnolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere a los compuestos de la fórmula así como las sales y ésteres farmacéuticamente aceptables de los mismos, en la que de R1 a R4 tienen los significados definidos en la reivindicación 1, pueden utilizarse en forma de composiciones farmacéuticas.
EC2008008082A 2005-07-05 2008-01-04 Derivados de piridazina ECSP088082A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05106098 2005-07-05

Publications (1)

Publication Number Publication Date
ECSP088082A true ECSP088082A (es) 2008-02-20

Family

ID=36781523

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2008008082A ECSP088082A (es) 2005-07-05 2008-01-04 Derivados de piridazina

Country Status (33)

Country Link
US (1) US7678795B2 (es)
EP (1) EP1904455B1 (es)
JP (1) JP4787321B2 (es)
KR (1) KR100979582B1 (es)
CN (1) CN101528713B (es)
AR (1) AR054814A1 (es)
AT (1) ATE520670T1 (es)
AU (1) AU2006265201C1 (es)
BR (1) BRPI0613565A2 (es)
CA (1) CA2612740C (es)
CL (1) CL2009001936A1 (es)
CR (1) CR9587A (es)
CY (1) CY1112401T1 (es)
DK (1) DK1904455T3 (es)
EC (1) ECSP088082A (es)
ES (1) ES2370039T3 (es)
HK (1) HK1134087A1 (es)
HR (1) HRP20110808T1 (es)
IL (1) IL188182A (es)
MA (1) MA29909B1 (es)
MX (1) MX2007016352A (es)
MY (1) MY144209A (es)
NO (1) NO20076431L (es)
NZ (1) NZ564260A (es)
PL (1) PL1904455T3 (es)
PT (1) PT1904455E (es)
RS (1) RS51994B (es)
RU (1) RU2401832C2 (es)
SI (1) SI1904455T1 (es)
TW (1) TWI323258B (es)
UA (1) UA94052C2 (es)
WO (1) WO2007003521A2 (es)
ZA (1) ZA200710972B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7834178B2 (en) 2006-03-01 2010-11-16 Bristol-Myers Squibb Company Triazine 11-beta hydroxysteroid dehydrogenase type 1 inhibitors
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
RU2009108280A (ru) 2006-08-08 2010-09-20 Санофи-Авентис (Fr) Ариламиноарилалкилзамещенные имидазолидин-2,4-дионы, способы их получения, содержащие эти соединения лекарственные средства и их применение
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US20090270398A1 (en) * 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, Compositions and Methods Comprising Pyridazine Derivatives
WO2009131958A2 (en) * 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, compositions and methods comprising triazine derivatives
WO2010003624A2 (en) 2008-07-09 2010-01-14 Sanofi-Aventis Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
US8501940B2 (en) 2008-07-15 2013-08-06 Hoffmann-La Roche Inc. Tetrahydrocinnoline derivatives
US20100022572A1 (en) 2008-07-18 2010-01-28 Kowa Company, Ltd. Novel spiro compound and medicine comprising the same
US8236789B2 (en) 2008-08-29 2012-08-07 Kowa Company, Ltd. 1-adamantyl azetidin-2-one derivatives and drugs containing same
TW201022210A (en) 2008-10-29 2010-06-16 Kowa Co 1,2-diazetidin-3-one derivatives and drugs containing same
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
US20100267706A1 (en) * 2009-04-20 2010-10-21 Institute For Oneworld Health Compounds, Compositions and Methods Comprising Pyridazine Derivatives
ES2350077B1 (es) 2009-06-04 2011-11-04 Laboratorios Salvat, S.A. Compuestos inhibidores de 11beta-hidroxiesteroide deshidrogenasa de tipo 1.
WO2011023754A1 (en) 2009-08-26 2011-03-03 Sanofi-Aventis Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120054A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
US8901114B2 (en) 2011-03-08 2014-12-02 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
MX2016005128A (es) * 2013-11-05 2016-07-18 Hoffmann La Roche Derivados de 5,6,7,8-tetahidro-5,8-metanocinolina como moduladores del receptor huerfano y relacionado con acido retinoico (rorc) para el tratamiento de enfermedades autoinmunes.
EP3235813A1 (en) 2016-04-19 2017-10-25 Cidqo 2012, S.L. Aza-tetra-cyclo derivatives
BR112019008821A8 (pt) * 2016-11-01 2020-02-04 Hoffmann La Roche derivados de piridazina como moduladores de rorc

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4607458B2 (ja) * 2002-02-05 2011-01-05 ハイ・ポイント・ファーマスーティカルズ、エルエルシー 新規なアリールおよびへテロアリールピペラジン
TWI314455B (en) * 2002-12-10 2009-09-11 Nippon Kayaku Kk 3-phenyl-cinnoline derivatives and anti-tumor agent containing the same
TW200503994A (en) 2003-01-24 2005-02-01 Novartis Ag Organic compounds
EP1615647B1 (en) 2003-04-11 2010-01-20 High Point Pharmaceuticals, LLC Pharmaceutical use of fused 1,2,4-triazoles

Also Published As

Publication number Publication date
CA2612740A1 (en) 2007-01-11
SI1904455T1 (sl) 2011-11-30
TW200738241A (en) 2007-10-16
UA94052C2 (uk) 2011-04-11
DK1904455T3 (da) 2011-09-12
RU2008103483A (ru) 2009-08-10
ZA200710972B (en) 2008-10-29
AU2006265201A1 (en) 2007-01-11
WO2007003521A2 (en) 2007-01-11
PT1904455E (pt) 2011-10-04
US20070010519A1 (en) 2007-01-11
EP1904455B1 (en) 2011-08-17
US7678795B2 (en) 2010-03-16
WO2007003521A3 (en) 2009-02-05
TWI323258B (en) 2010-04-11
KR20080019272A (ko) 2008-03-03
AR054814A1 (es) 2007-07-18
BRPI0613565A2 (pt) 2011-01-18
CA2612740C (en) 2011-07-26
RU2401832C2 (ru) 2010-10-20
CY1112401T1 (el) 2015-12-09
RS51994B (en) 2012-04-30
CR9587A (es) 2008-01-25
AU2006265201C1 (en) 2010-12-09
JP2009500370A (ja) 2009-01-08
NZ564260A (en) 2010-12-24
NO20076431L (no) 2008-04-01
CL2009001936A1 (es) 2010-02-19
AU2006265201B2 (en) 2010-07-15
ES2370039T3 (es) 2011-12-12
CN101528713B (zh) 2013-05-22
PL1904455T3 (pl) 2012-01-31
ATE520670T1 (de) 2011-09-15
IL188182A0 (en) 2008-03-20
IL188182A (en) 2011-10-31
JP4787321B2 (ja) 2011-10-05
HRP20110808T1 (hr) 2011-12-31
EP1904455A2 (en) 2008-04-02
MY144209A (en) 2011-08-15
MX2007016352A (es) 2008-03-05
CN101528713A (zh) 2009-09-09
MA29909B1 (fr) 2008-11-03
HK1134087A1 (en) 2010-04-16
KR100979582B1 (ko) 2010-09-01

Similar Documents

Publication Publication Date Title
ECSP088082A (es) Derivados de piridazina
CR9703A (es) Derivados de pirazolona
ECSP088549A (es) Nuevos derivados de pirrol fusionado
MY138941A (en) Aryl-pyridine derivatives
UY30500A1 (es) Compuestos de azabencimidazolilo
ECSP099750A (es) Imidazoquinolinas con propiedades inmunomoduladoras
UY31189A1 (es) Compuestos heterocíclicos
CR20110219A (es) Ácidos naftilacéticos
AR072261A1 (es) Derivados piperazin-pirazolicos, composiciones farmaceuticas que los contienen y usos de los mismos como agentes anticancerigenos.
CR11454A (es) Derivados de isoxazolo-piridina
AR051577A1 (es) Derivados eter sustituidos por hexafluorisopropanol
UY29963A1 (es) Compuestos terapéuticos: piridinas y pirazinas como andamios
UY31870A (es) Receptor metabotrópico de glutamato potenciadores 286
SG148178A1 (en) Indozolone derivatives as 11b-hsd1 inhibitors
MX2010005824A (es) Derivados de aminotiazol.
DOP2011000134A (es) Lactamas como inhibidores de beta secretasa
AR063027A1 (es) Derivados de sulfonamida
ECSP11011555A (es) Sulfonamidas heterocíclicas, usos y composiciones farmacéuticas de las mismas
UY35182A (es) ?COMPUESTOS DE HEXAHIDROPIRANO[ 3,4-d][1,3]TIAZIN-2-AMINA? .
ECSP099442A (es) Derivados de heteroaril-pirrolidinil- y -piperidinil-cetona
DOP2010000317A (es) Nueva clase de espiro piperidinas para el tratamiento de enfermedades neurodegenerativas
AR048589A1 (es) Derivados de pirrolidina -3,4-dicarboxamida
UY31000A1 (es) Oxoisoxazoles como inhibidores de lipasas y fosfolipasas
UY27975A1 (es) Derivados de indolilo
UY27930A1 (es) Derivados de tiazol